These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30374059)

  • 1. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes.
    Veiga N; Goldsmith M; Granot Y; Rosenblum D; Dammes N; Kedmi R; Ramishetti S; Peer D
    Nat Commun; 2018 Oct; 9(1):4493. PubMed ID: 30374059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target.
    Veiga N; Goldsmith M; Diesendruck Y; Ramishetti S; Rosenblum D; Elinav E; Behlke MA; Benhar I; Peer D
    J Control Release; 2019 Nov; 313():33-41. PubMed ID: 31634546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint.
    Granot Y; Peer D
    Semin Immunol; 2017 Dec; 34():68-77. PubMed ID: 28890238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles.
    Ramishetti S; Landesman-Milo D; Peer D
    J Drug Target; 2016 Nov; 24(9):780-786. PubMed ID: 27030014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
    Yanez Arteta M; Kjellman T; Bartesaghi S; Wallin S; Wu X; Kvist AJ; Dabkowska A; Székely N; Radulescu A; Bergenholtz J; Lindfors L
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3351-E3360. PubMed ID: 29588418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
    Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
    ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.
    Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V
    Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
    Sato Y; Matsui H; Sato R; Harashima H
    J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver.
    Miao L; Lin J; Huang Y; Li L; Delcassian D; Ge Y; Shi Y; Anderson DG
    Nat Commun; 2020 May; 11(1):2424. PubMed ID: 32415122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Nanoprimer To Improve the Systemic Delivery of siRNA and mRNA.
    Saunders NRM; Paolini MS; Fenton OS; Poul L; Devalliere J; Mpambani F; Darmon A; Bergère M; Jibault O; Germain M; Langer R
    Nano Lett; 2020 Jun; 20(6):4264-4269. PubMed ID: 32357299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis.
    Huang Y; Guo J; Gui S
    Eur J Pharm Sci; 2018 Dec; 125():232-243. PubMed ID: 30315858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.
    Sato Y; Note Y; Maeki M; Kaji N; Baba Y; Tokeshi M; Harashima H
    J Control Release; 2016 May; 229():48-57. PubMed ID: 26995758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
    Hashiba K; Sato Y; Harashima H
    J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.
    Zhang Y; Arrington L; Boardman D; Davis J; Xu Y; DiFelice K; Stirdivant S; Wang W; Budzik B; Bawiec J; Deng J; Beutner G; Seifried D; Stanton M; Gindy M; Leone A
    J Control Release; 2014 Jan; 174():7-14. PubMed ID: 24240015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.
    Beloqui A; Coco R; Alhouayek M; Solinís MÁ; Rodríguez-Gascón A; Muccioli GG; Préat V
    Int J Pharm; 2013 Oct; 454(2):775-83. PubMed ID: 23694806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.
    Peer D; Park EJ; Morishita Y; Carman CV; Shimaoka M
    Science; 2008 Feb; 319(5863):627-30. PubMed ID: 18239128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
    Pardi N; Tuyishime S; Muramatsu H; Kariko K; Mui BL; Tam YK; Madden TD; Hope MJ; Weissman D
    J Control Release; 2015 Nov; 217():345-51. PubMed ID: 26264835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis.
    Mikami S; Nakase H; Yamamoto S; Takeda Y; Yoshino T; Kasahara K; Ueno S; Uza N; Oishi S; Fujii N; Nagasawa T; Chiba T
    J Pharmacol Exp Ther; 2008 Nov; 327(2):383-92. PubMed ID: 18716065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.